Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1701 to 1750 of 3765 results for treatment

  1. What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment in babies, children and young people with chemotherapy-induced nausea or vomiting which persists with optimised conventional antiemetics?

    and cost effectiveness of cannabis-based medicinal products as an add-on treatment in babies, children and young people with...

    Research recommendation
    Published
    10 February 2020

  2. Comparative research is recommended in the UK to reduce uncertainty about the outcomes of patients with chronic, 'hard-to-heal', complex wounds treated by the MIST Therapy system compared with those treated by standard methods of wound care. This research should define the types and chronicity of wounds being treated and the details of other treatments being used. It should report healing rates, durations of treatment (including debridement) needed to achieve healing, and quality of life measures (including quality of life if wounds heal only partially). It is recommended that centres using the MIST Therapy system take part in research that delivers these outcomes. Current users of the MIST Therapy system who are unable to join research studies should use NICE's audit criteria to collect further information on healing rates, duration of treatment and quality of life and publish their results.

    being treated and the details of other treatments being used. It should report healing rates, durations of treatment...

    Research recommendation
    Published
    9 June 2015

  3. What is the most clinically and cost-effective follow‑up protocol for people with prostate cancer who have had radical treatment, with specific regard to risk stratification, duration of follow‑up, frequency of follow‑up appointments, the type of examination or blood tests, and the roles of primary and secondary care in follow‑up?

    follow‑up protocol for people with prostate cancer who have had radical treatment, with specific regard to risk stratification, duration...

    Research recommendation
    Published
    25 October 2019

  4. Aspirin treatment in acute ischaemic stroke: Should a person who has a stroke or a TIA and is already taking aspirin be prescribed the same or an increased dose of aspirin after the stroke?

    Recommendation ID NG128/06 Question Aspirin treatment in acute ischaemic stroke: Should a person who has a stroke or a TIA and is already

    Research recommendation
    Published
    11 May 2022

  5. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (HTG356)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.

    HealthTech guidance
    Published
    12 November 2014
    View recommendations

    Sections for HTG356

  6. What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with persistent nausea or vomiting not caused by chemotherapy which hasn't fully responded to optimised conventional antiemetics?

    and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with persistent nausea or vomiting not...

    Research recommendation
    Published
    10 February 2020

  7. pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms (MIB222)

    NICE has developed a medtech innovation briefing (MIB) on pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms .

    Medtech innovation briefing
    Published
    11 August 2020

  8. Stretta System for gastro-oesophageal reflux disease (MIB74)

    NICE has developed a medtech innovation briefing (MIB) on the Stretta System for gastro-oesophageal reflux disease

    Medtech innovation briefing
    Published
    26 July 2016

  9. The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters (HTG368)

    Evidence-based recommendations on the Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters.

    HealthTech guidance
    Last updated
    30 May 2019
    View recommendations

    Sections for HTG368

  10. Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment (HTG756)

    Early value assessment (EVA) guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments.

    HealthTech guidance
    Published
    24 July 2025
    View recommendations

    Sections for HTG756

  11. NICE encourages the company, NHS England and treatment centres to collect more evidence, particularly on the longer-term benefits and costs of eliglustat and enzyme replacement therapy for treating type 1 Gaucher disease.

    HST5/1 Question NICE encourages the company, NHS England and treatment centres to collect more evidence, particularly on the longer-term...

    Research recommendation
    Published
    12 October 2018

  12. What are the components of a decision aid to support people referred for elective joint replacement in making decisions about their treatment (for example, the type of procedure, timing and implant choice)?

    referred for elective joint replacement in making decisions about their treatment (for example, the type of procedure, timing and...

    Research recommendation
    Published
    10 August 2020

  13. Effect of specialist services on health-related quality of life:- For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    and (b) provision of adrenaline injectors, when compared with emergency treatment alone? Any explanatory notes(if applicable) Why this...

    Research recommendation
    Published
    9 June 2015

  14. MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)

    NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .

    Medtech innovation briefing
    Published
    18 January 2018

  15. Premature ejaculation: dapoxetine (ESNM40)

    Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making

    Evidence summary
    Published
    14 May 2014

  16. Irreversible electroporation for treating liver metastases (IPG445)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

    Interventional procedures guidance
    Published
    23 February 2013
    View recommendations

    Sections for IPG445

  17. Immunoscore for predicting risk of colon cancer relapse (MIB269)

    NICE has developed a medtech innovation briefing on Immunoscore for predicting risk of colon cancer relapse .

    Medtech innovation briefing
    Published
    3 August 2021

  18. Safety and efficacy of antimuscarinics:- What is the safety and efficacy of more recently developed antimuscarinics compared with (a) placebo/usual care and (b) other antimuscarinics in the treatment of neurogenic lower urinary tract dysfunction?

    compared with (a) placebo/usual care and (b) other antimuscarinics in the treatment of neurogenic lower urinary tract dysfunction? Any...

    Research recommendation
    Published
    9 June 2015

  19. Factors that may be barriers to successfully managing chronic pain, including chronic primary pain: What risk factors enable stratification of treatment for people aged 16 years and over with chronic pain?

    including chronic primary pain: What risk factors enable stratification of treatment for people aged 16 years and over with chronic...

    Research recommendation
    Published
    6 August 2021

  20. Managing medicines for adults receiving social care in the community (NG67)

    This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.

    NICE guideline
    Published
    30 March 2017
    View recommendations

    Sections for NG67

  21. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

    In development Reference number: GID-TA11279 Expected publication date:  21 January 2026

    Technology appraisal guidance
    In development

  22. Managing anaemia – optimal Hb levels for children and young people: What is the efficacy and safety of different aspirational haemoglobin (Hb) targets for children and young people with CKD undergoing treatment for anaemia?

    haemoglobin (Hb) targets for children and young people with CKD undergoing treatment for anaemia? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    30 September 2021

  23. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

    Medtech innovation briefing
    Published
    4 February 2014

  24. Service provision for neutropenic sepsis in patients with cancer:- A prospective national cohort study should be carried out to assess the incidence of suspected and proven neutropenic sepsis in patients having anticancer treatment.

    suspected and proven neutropenic sepsis in patients having anticancer treatment. Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    9 June 2015

  25. Gastroparesis in adults: oral erythromycin (ESUOM13)

    Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    18 June 2013

  26. Trauma (QS166)

    This quality standard covers assessing and managing trauma (complex fractures, non-complex fractures, major trauma and spinal injury) in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    29 March 2018
    View quality statements

    Sections for QS166

  27. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development Reference number: GID-TA11439 Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)

    NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .

    Medtech innovation briefing
    Published
    19 November 2014

  29. How many confirmatory diagnostic biopsies are carried out before definitive treatment, in people who have a clinical diagnosis of basal cell carcinoma and which different modalities used to treat basal cell carcinoma?

    many confirmatory diagnostic biopsies are carried out before definitive treatment, in people who have a clinical diagnosis of basal cell...

    Research recommendation
    Published
    12 January 2016

  30. Transcutaneous electrical stimulation of the trigeminal nerve for ADHD (IPG748)

    Evidence-based recommendations on transcutaneous electrical stimulation of the trigeminal nerve for ADHD. This involves a single-use electrode patch stuck to the forehead, which sends small electrical pulses through the skin during sleep.

    Interventional procedures guidance
    Published
    11 January 2023
    View recommendations

    Sections for IPG748

  31. NICE encourages further research into radiofrequency ablation of the soft palate for snoring. This could take the form of data collection, with the specific aim of documenting long-term outcomes and the need for further treatment.

    specific aim of documenting long-term outcomes and the need for further treatment. Any explanatory notes(if applicable) Current evidence...

    Research recommendation
    Published
    9 June 2015

  32. StoneChecker for kidney stone evaluation (MIB171)

    NICE has developed a medtech innovation briefing (MIB) on StoneChecker for kidney stone evaluation .

    Medtech innovation briefing
    Published
    1 February 2019

  33. Depression and anxiety: biopsychosocial assessment at diagnosis (IND103)

    This indicator covers the percentage of patients with a new diagnosis of depression in the preceding 1 April to 31 March who have had a bio-psychosocial assessment by the point of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM49

    General practice indicators suitable for use in QOF
    Last updated
    29 June 2022

  34. Newly diagnosed seizures (focal and generalised) – monotherapy: How do the newer AEDs compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy? Focal seizures: carbamazepine, eslicarbazepine acetate, lacosamide, lamotrigine, levetiracetam, pregabalin  and zonisamide. Generalised seizures: lamotrigine, levetiracetam, sodium valproate and zonisamide.

    How do the newer AEDs compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy? Focal seizures:...

    Research recommendation
    Published
    13 August 2021

  35. High-intensity focused ultrasound for prostate cancer (IPG118)

    Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.

    Interventional procedures guidance
    Published
    23 March 2005
    View recommendations

    Sections for IPG118

  36. Grenz rays therapy for inflammatory skin conditions (IPG236)

    Evidence-based recommendations on Grenz rays therapy for inflammatory skin conditions. This involves exposing the skin to low-energy, non-penetrative electromagnetic radiation.

    Interventional procedures guidance
    Published
    28 November 2007
    View recommendations

    Sections for IPG236

  37. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

    Interventional procedures guidance
    Published
    26 June 2015
    View recommendations

    Sections for IPG524

  38. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued Reference number: GID-TAG408

    Technology appraisal guidance
    Discontinued

  39. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    20 June 2017

  40. EpiFix for chronic wounds (MIB139)

    NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .

    Medtech innovation briefing
    Published
    30 January 2018

  41. Extracranial to intracranial bypass for intracranial atherosclerosis (IPG596)

    Evidence-based recommendations on extracranial to intracranial bypass for intracranial atherosclerosis. This involves joining a blood vessel from outside the skull to one inside the skull to bypass a narrowed or partially blocked vessel.

    Interventional procedures guidance
    Published
    8 November 2017
    View recommendations

    Sections for IPG596

  42. Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)

    NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma

    Medtech innovation briefing
    Published
    11 July 2016

  43. Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

    Discontinued Reference number: GID-HST10004

    Highly specialised technologies guidance
    Discontinued

  44. Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain (HTG498)

    Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

    HealthTech guidance
    Published
    23 January 2019
    View recommendations

    Sections for HTG498

  45. Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)

    Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).

    HealthTech guidance
    Published
    4 July 2018
    View recommendations

    Sections for HTG476

  46. NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate, was sensitive to whether the patient access scheme would be realised in clinical practice. The Committee agreed that it would be critical to generate evidence to support the following: - The proportion of people who become eligible for the patient access scheme, that is, that they remain on treatment beyond 26 cycles. - The benefit of lenalidomide after 26 cycles, that is the associated overall survival and health related quality of life for those who remain on treatment beyond 26 cycles.

    become eligible for the patient access scheme, that is, that they remain on treatment beyond 26 cycles. - The benefit of lenalidomide...

    Research recommendation
    Published
    9 June 2015

  47. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)

    Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.

    Interventional procedures guidance
    Published
    2 April 2024
    View recommendations

    Sections for IPG784

  48. Register your organisation as a stakeholder

    Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.

  49. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date: TBC

    Interventional procedures guidance
    In development

  50. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 19 December 2025.

    Interventional procedures guidance
    In consultation